N,N,N'-Trimethyl-succinamid | 27846-70-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N,N'-Trimethyl-succinamid
• 英文别名: N,N',N'-trimethylbutanediamide
• CAS: 27846-70-4
• 化学式: C₇H₁₄N₂O₂
• 分子量: 158.2
• InChiKey: CVKJFDZBUUGCPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N,N'-Trimethyl-succinamid 在 lithium aluminium tetrahydride 作用下， 以 1,4-二氧六环 为溶剂， 生成 N,N,N'-三甲基-1,4-丁二胺
  参考文献：
  名称：

  Ripperger,H. et al., Journal fur praktische Chemie (Leipzig 1954), 1970, vol. 312, p. 449 - 455

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N-二甲基琥珀酰胺酸 以 乙醚 、 乙醇 为溶剂， 生成 N,N,N'-Trimethyl-succinamid
  参考文献：
  名称：

  Ripperger,H. et al., Journal fur praktische Chemie (Leipzig 1954), 1970, vol. 312, p. 449 - 455

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY<br/>[FR] DERIVES AMIDES HETEROCYCLIQUES POSSEDANT UNE ACTIVITE INHIBITRICE DE GLYCOGENE PHOSPHORYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2005018637A1

  公开（公告）日：2005-03-03

  A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example: R4 and R5 together are either -S-C(R6=C(R7)- or -C(R7)=C(R6)-S- ; R6 and R7 are independently selected from hydrogen and halo; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is halo, cyano or carboxy; R2 is for example methyl; R3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.

  该化合物的分子式为（1）或其药用可接受的盐或前药；（1）其中，例如：R4和R5一起是-S-C(R6=C(R7)-或-C(R7)=C(R6)-S-；R6和R7分别选择自氢和卤素；A是苯基或杂环芳基；n为0、1或2；R1为卤素、氰基或羧基；R2为例如甲基；R3为例如选择自卤(1-4C)烷基、二卤(1-4C)烷基、三氟甲基、羟基(1-4C)烷基、二羟基(2-4C)烷基、三羟基(3-4C)烷基、氰基(1-4C)烷基（在烷基上可选择性地取代羟基）、（1-4C)烷氧基(1-4C)烷基、（1-4C)烷氧基(1-4C)烷氧基(1-4C)烷基、二[(1-4C)烷氧](1-4C)烷基、(羟基)[(1-4C)烷氧](1-4C)烷基；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备化合物和含有它们的药物组合物的方法。
• MIXTURES OF ITACONIC ACID OR ITACONIC ACID DERIVATIVES AND PRIMARY AMINES FOR PRODUCING 1,3- AND 1,4-ALKYL METHYL PYRROLIDONES
  申请人：Wabnitz Tobias

  公开号：US20110251119A1

  公开（公告）日：2011-10-13

  The present invention relates to a mixture comprising itaconic acid or an itaconic acid derivative and a primary amine of the formula (I) R—NH 2 (I) where the molar ratio of primary amine to itaconic acid or the itaconic acid derivative is in the range from 0.5:1 to 20:1, wherein the mixture comprises 50 mole percent or less of 4-carboxypyrrolidones of the formula (II), derivatives of the 4-carboxypyrrolidones of the formula (II) and 4-carbamidopyrrolidones of the formula (III) based on the itaconic acid used or the itaconic acid derivative used and in which R is a linear or branched saturated aliphatic radical having 1 to 24 carbon atoms or a saturated cycloaliphatic radical having 3 to 24 carbon atoms. The invention further provides for the use of the inventive mixtures for preparing 1,3-alkylmethylpyrrolidones and/or 1,4-alkylmethylpyrrolidones, and also a process for preparing 1,3-alkylmethylpyrrolidones and/or 1,4-alkylmethylpyrrolidones. In addition, the present invention relates to mixtures comprising 1,3-alkylmethylpyrrolidones and/or 1,4-alkylmethylpyrrolidones and 1,3-alkylmethylpyrrolidines, where the proportion of 1,3-alkylmethylpyrrolidines is in the range from 10 to 10 000 ppm, and to mixtures comprising 1,3-alkylmethylpyrrolidone and 1,4-alkylmethylpyrrolidone, wherein the molar ratio of 1,3-alkylmethylpyrrolidone to 1,4-alkylmethylpyrrolidone is in the range from 1:1 to 10:1.

  本发明涉及一种混合物，包括吡啶二酸或吡啶二酸衍生物和式（I）的一种主要胺，其中主要胺与吡啶二酸或吡啶二酸衍生物的摩尔比在0.5:1到20:1的范围内，其中混合物包括50摩尔％或更少的基于所使用的吡啶二酸或吡啶二酸衍生物的式（II）的4-羧基吡咯烷酮衍生物和4-羟基吡咯烷酮衍生物以及基于所使用的吡啶二酸或吡啶二酸衍生物的式（III）的4-氨基吡咯烷酮衍生物，其中R是具有1至24个碳原子的线性或支链饱和脂肪基或具有3至24个碳原子的饱和环脂基。该发明还提供了使用该混合物制备1,3-烷基甲基吡咯烷酮和/或1,4-烷基甲基吡咯烷酮的方法，以及制备1,3-烷基甲基吡咯烷酮和/或1,4-烷基甲基吡咯烷酮的方法。此外，本发明还涉及包含1,3-烷基甲基吡咯烷酮和/或1,4-烷基甲基吡咯烷酮和1,3-烷基甲基吡咯烷的混合物，其中1,3-烷基甲基吡咯烷的比例在10至10,000 ppm的范围内，并且涉及包含1,3-烷基甲基吡咯烷酮和1,4-烷基甲基吡咯烷酮的混合物，其中1,3-烷基甲基吡咯烷酮与1,4-烷基甲基吡咯烷酮的摩尔比在1:1到10:1的范围内。
• Substituted hydroxyethylamines
  申请人：John Varghese

  公开号：US20060106256A1

  公开（公告）日：2006-05-18

  This invention relates to prodrugs of a class of amine compounds which are useful in the treatment of Alzheimer's disease and similar diseases.

  本发明涉及一类氨基化合物的前药，该类化合物在治疗阿尔茨海默病和类似疾病方面具有用途。
• N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
  申请人：John Varghese

  公开号：US20070213316A1

  公开（公告）日：2007-09-13

  Disclosed are compounds of the formula wherein the variables R N , R C , R 1 , R 25 , R 2 , and R 3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of discorders such as Alzheimer's Disease.

  本发明揭示了以下式子的化合物：其中变量RN，RC，R1，R25，R2和R3如本文所定义。这些化合物具有抑制β-分泌酶的活性，因此可用于治疗多种疾病，例如阿尔茨海默病。
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。